Multiple Myeloma

Extended follow-up from the CASSIOPEIA trial illustrates the PFS and MRD benefits of daratumumab-based induction/consolidation and maintenance therapy.

A subgroup analysis from the PERSEUS trial showed sustained PFS benefit in patients with newly diagnosed multiple myeloma receiving D-VRd.

Responses appear to improve over time in those with transplant-eligible newly diagnosed multiple who receive the belantamab mafodotin-based combination.

Combination therapy with JAK inhibitors may help improve efficacy outcomes for patients with multiple myeloma.

James R. Berenson, MD, discussed adverse effects associated with oral ruxolitinib plus selinexor in patients with multiple myeloma.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, gave a high-level overview of teclistamab use in the MajesTEC-1 trial.

Experts highlighted the use of GPRC5D therapy in patients with multiple myeloma.

Findings from the phase 3 IMROZ trial support the FDA approval of the combination therapy for newly diagnosed not eligible for ASCT multiple myeloma.

Experts on multiple myeloma offer clinical insights on preparing patients who are going to receive GPRC5D therapy, highlighting step-up and treatment dosing for talquetamab.

Beth Faiman, CNP, PhD, outlines unique toxicities seen with other GPRC5D-targeted therapies in multiple myeloma.

Focusing on clinical trials evaluating combination strategies with bispecifics, Larysa J. Sanchez, MD, discusses the TRIMM-2, TRIMM-3, and MajesTEC-3 studies.

Rafael Fonseca, MD, discusses the MonumenTAL-2 and MonumenTAL-3 clinical trials investigating talquetamab combination strategies in relapsed/refractory multiple myeloma.

Ruxolitinib, currently approved as treatment for patients with myelofibrosis and polycythemia vera, is currently undergoing evaluation in myeloma studies.

A belantamab mafodotin combination regimen has been accepted for review in Japan, based on data from the DREAMM-7 and DREAMM-8 clinical trials.

Hematologist-oncologists discuss GPRC5D-targeting treatments that are currently in development for patients with relapsed/refractory multiple myeloma.

Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.

Noopur Raje, MD, shares clinical perspectives on her experience treating patients with prior BCMA bispecific exposure and provides insights on adverse event management practices in patients receiving talquetamab.

Lisa Hwa, APRN, DNP, CNP, FAPO, describes the unique challenges in managing adverse events associated with GPRC5D therapy compared with other bispecifics.

Community and academic oncologists discussed how effective communication between practices can enhance multiple myeloma outcomes.

Larysa J. Sanchez, MD, discusses recent efficacy data presented at EHA 2024 from the long-term follow-up results of the phase 1/2 MonumenTAL-1 study investigating talquetamab in relapsed/refractory multiple myeloma.

A panel of experts on multiple myeloma discuss the importance of GPRC5D as a target of interest in relapsed/refractory disease and discuss their experiences with talquetamab in clinical practice.

“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.

Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.

Surbhi Sidana, MD, spoke about multiple myeloma developments with the potential to impact clinical practice, particularly early line use of bispecific antibodies.

A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.

Surbhi Sidana, MD, discussed LINKER-MM1 trial efficacy findings, in which linvoseltamab was evaluated in patients with relapsed/refractory multiple myeloma.

Surbhi Sidana, MD, discussed outpatient supportive care for patients following immunotherapy treatment for hematologic cancers.

Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.

Minimal residual disease as an end point in multiple myeloma has been widely discussed and was even a topic of a recent ODAC meeting.

Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.